The variables included age, menstrual status, breast cancer status, DFS, adjuvant endocrine therapy, adjuvant chemotherapy, adjuvant radiotherapy, number of metastases, metastatic site, PR status, HER2 status, Ki-67 index, endocrine drugs, and first-line POD24 (only included in OS analysis). This evidence concerns the gene MKI67 and breast cancer.